JCRRF
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q4 | 3.58 | $10.0B | — |
| 2025 Q3 | 0.28 | $9.0B | — |
| 2025 Q2 | 18.77 | $13.0B | — |
| 2025 Q1 | -4.48 | $59M | $0 |
| 2025 Q4 | -34.28 | $7.2B | $0 |
| 2024 Q3 | 0.93 | $9.2B | $0 |
| 2024 Q2 | -7.15 | $8.5B | $0 |
| 2024 Q1 | 1.61 | $8.1B | $0 |